tert-butyl 4-((4-methoxyphenyl)carbamoyl)piperazine-1-carboxylate | 1326394-37-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: tert-butyl 4-((4-methoxyphenyl)carbamoyl)piperazine-1-carboxylate
• 英文别名: 1,1-Dimethylethyl 4-[[(4-methoxyphenyl)amino]carbonyl]-1-piperazinecarboxylate；tert-butyl 4-[(4-methoxyphenyl)carbamoyl]piperazine-1-carboxylate
• CAS: 1326394-37-9
• 化学式: C₁₇H₂₅N₃O₄
• 分子量: 335.403
• InChiKey: NGOZFIWKAICURO-UHFFFAOYSA-N

物化性质

• 沸点：
  516.6±50.0 °C(Predicted)
• 密度：
  1.204±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  24
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.53
• 拓扑面积：
  71.1
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  tert-butyl 4-((4-methoxyphenyl)carbamoyl)piperazine-1-carboxylate 在 碳酸氢钠 、 N,N-二异丙基乙胺 、 三氟乙酸 、 lithium hydroxide 作用下， 以 二氯甲烷 、 水 、 丙酮 为溶剂， 反应 4.5h， 生成 (2S)-2-[[4-[(4-methoxyphenyl)carbamoyl]piperazine-1-carbonyl]amino]-4-methylpentanoic acid
  参考文献：
  名称：

  Covalent docking modelling-based discovery of tripeptidyl epoxyketone proteasome inhibitors composed of aliphatic-heterocycles

  摘要：

  The potential of specific proteasome inhibitors to act as anti-cancer agents has attracted intensive investigations. The proteasome can be covalently inhibited by epoxyketone derivatives via a two-step reaction. Several computational approaches have been developed to mimic the covalent binding event. Compound 1 composed of a six-membered heterocyclic ring was designed by using covalent docking. With a possible different binding mode from the clinical compound Carfilzomib, it occupied the 55 pocket of 20S proteasome and showed favorable inhibitory activity. Subsequently optimization and evaluation were taken place. Among these compounds, 11h demonstrated extraordinary in vitro inhibitory activity and selectivity, and good in vivo proteasome inhibitory activity, a favorable pharmacokinetic profile and xenograft tumor inhibition. The possible binding pattern of compound 11h against proteasome was further fully explored via calculations, providing a theoretical basis for finding potent proteasome inhibitors. (C) 2018 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2018.12.064
• 作为产物：
  描述：

  甲氧苯胺 以 二氯甲烷 、 二甲基亚砜 为溶剂， 反应 4.0h， 生成 tert-butyl 4-((4-methoxyphenyl)carbamoyl)piperazine-1-carboxylate
  参考文献：
  名称：

  苯喹啉瞬态受体潜在的香草酸1拮抗剂治疗疼痛：1-（2-苯基喹啉-4-羰基）-N-（4-（三氟甲基）苯基）吡咯烷-3-羧酰胺的发现

  摘要：

  本文报道的是设计，合成和药理学表征的一类在从喹古芬铅进化而来的苯基喹啉平台上构建的TRPV1拮抗剂。该设计包括三个部分：连接到脂族羧酰胺的苯基喹啉头基，该端基被束缚在苯基尾基上。该设计的优化导致鉴定出37个，其中包括一个吡咯烷连接子和一个三氟甲基-苯基尾巴。在TRPV1功能测定中，使用表达hTRPV1的细胞，有37种拮抗辣椒素诱导的Ca 2+内流，IC 50值为10.2 nM。在完整的小鼠镇痛模型中，37在不同的疼痛模型中，与阳性对照BCTC相比，它们显示出更好的抗伤害感受活性。所有这些结果表明，可以考虑将37种药物作为抗伤害性药物进一步开发的主要候选药物。

  DOI：

  10.1016/j.bmc.2017.12.048

文献信息

• [EN] MODULATORS OF VASOPRESSIN RECEPTORS WITH THERAPEUTIC POTENTIAL<br/>[FR] MODULATEURS DES RÉCEPTEURS DE LA VASOPRESSINE À POUVOIR THÉRAPEUTIQUE
  申请人：SCRIPPS RESEARCH INST

  公开号：WO2014127350A1

  公开（公告）日：2014-08-21

  Compounds comprising piperazines, piperidines, spiro-furanopiperidines, and analogs thereof are provided that are modulators, such as positive allosteric modulators, of one or more subclasses of vasopressin receptors. The compounds can be selective modulators of one or more subclasses of vasopressin receptors. Compounds of the invention can be used in the treatment of a condition wherein modulating a vasopressin receptor is medically indicated for treatment of the condition.

  提供了包含哌嗪、哌啶、螺环呋喃哌啶及其类似物的化合物，这些化合物是利钠素受体的调节剂，如正向变构调节剂，可以调节一个或多个亚类别的利钠素受体。这些化合物可以是一个或多个亚类别的利钠素受体的选择性调节剂。本发明的化合物可用于治疗需要调节利钠素受体的情况。
• Synthesis, biological activities and docking studies of pleuromutilin derivatives with piperazinyl urea linkage
  作者：Yuanyuan Zhang、Chuan Xie、Yang Liu、Feng Shang、Rushiya Shao、Jing Yu、Chunxia Wu、Xinghui Yao、Dongfang Liu、Zhouyu Wang

  DOI：10.1080/14756366.2021.1900163

  日期：2021.1.1

  promising antibiotic candidate. In this study, a series of novel pleuromutilin derivatives possessing piperazinyl urea linkage were efficiently synthesised, and their antibacterial activities and bactericidal properties were evaluated via MIC, MBC and Time-kill kinetics assays. The results showed that all compounds exhibited potent activities against tested strains, especially MRSA strains with MIC values

   抽象的 抗生素耐药性变得越来越普遍，几乎涉及市场上所有的抗生素。由耐药细菌（例如 MRSA）引起的疾病死亡率很高，并对公众健康产生负面影响。新药的开发将是解决这一问题的有效手段。基于生物活性天然产物的修饰可以大大缩短药物开发时间并提高成功率。截短侧耳素是一种来自担子菌的天然产物，是一种有前途的候选抗生素。本研究高效合成了一系列具有哌嗪基脲键的新型截短侧耳素衍生物，并通过 MIC、MBC 和 Time-kill 动力学测定评估了它们的抗菌活性和杀菌特性。结果表明，所有化合物均对受试菌株表现出有效的活性，特别是对MRSA菌株，MIC值低至0.125 μg/mL；比市售抗生素泰妙菌素低8倍。对接研究表明取代的哌嗪基脲衍生物可以提供氢键并引发分子和周围残基之间的π-π堆积。
• TCT-mediated click chemistry for the synthesis of nitrogen-containing functionalities: conversion of carboxylic acids to carbamides, carbamates, carbamothioates, amides and amines
  作者：Riyaz Ahmed、Ria Gupta、Zaheen Akhter、Mukesh Kumar、Parvinder Pal Singh

  DOI：10.1039/d2ob00324d

  日期：——

  s-trichlorotriazine (TCT, also known as cyanuric chloride) mediated one-pot general method for the conversion of carboxylic acids into ubiquitous functionalities such as carbamides, carbamates, carbamothioates, amides, and amines. The TCT-mediated activation of acids followed by azidation and heating led to the isocyanate formation via Curtius rearrangement which involves click chemistry in the presence of nucleophiles

  在这里，我们报告了一种s-三氯三嗪（TCT，也称为三聚氯氰）介导的一锅通用方法，用于将羧酸转化为普遍存在的官能团，例如尿酰胺、氨基甲酸酯、氨基甲酸酯、酰胺和胺。TCT 介导的酸活化，然后是叠氮化和加热导致异氰酸酯通过Curtius 重排，涉及在亲核试剂存在下的点击化学并提供偶联产物。相对于起始材料，TCT 的使用量≤40 mol%；然而，它的大量可用性和低成本为其在功能分子合成中的适用性提供了独特的机会。优化的条件也已成功地用于克级合成和天然产物和药物（如鬼臼毒素、丁香酚、薯蓣皂苷元、香叶醇和氟伏沙明）的后期功能化。
• 1,3,4-oxadiazole derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same
  申请人：Chong Kun Dang Pharmaceutical Corp.

  公开号：US10717716B2

  公开（公告）日：2020-07-21

  The present invention relates to novel compounds having histone deacetylase 6 (HDAC6) in-hibitory activity, stereoisomers thereof or pharmaceutically acceptable salts thereof the use thereof for the preparation of therapeutic medicaments, pharmaceutical compositions containing the same, a method for treating diseases using the composition, and methods for preparing the novel compounds. The novel compounds stereoisomers thereof or pharmaceutically acceptable salts thereof according to the present invention have histone deacetylase (HDAC) inhibitory activity and are effective for the prevention or treatment of HDAC6-mediated diseases, including infectious diseases; neoplasms; endocrine, nutritional and metabolic diseases; mental and be-havioral disorders; neurological diseases; diseases of the eye and adnexa; cardiovascular diseases; respiratory diseases; digestive diseases; diseases of the skin and subcutaneous tissue; diseases of the musculoskeletal system and connective tissue; or congenital malformations, deformations and chromosomal abnormalities.

  本发明涉及具有组蛋白去乙酰化酶6(HDAC6)抑制活性的新型化合物、其立体异构体或其药学上可接受的盐，其在制备治疗药物中的用途，含有其的药物组合物，使用该组合物治疗疾病的方法，以及制备该新型化合物的方法。根据本发明的新型化合物立体异构体或其药学上可接受的盐具有组蛋白去乙酰化酶（HDAC）抑制活性，可有效预防或治疗HDAC6介导的疾病，包括感染性疾病、肿瘤、内分泌、营养和代谢性疾病；精神和行为障碍；神经系统疾病；眼睛和附件疾病；心血管疾病；呼吸系统疾病；消化系统疾病；皮肤和皮下组织疾病；肌肉骨骼系统和结缔组织疾病；或先天性畸形、变形和染色体异常。
• WO2017/23133
  申请人：——

  公开号：——

  公开（公告）日：——